title: Minilaparotomy radical retropubic prostatectomy: updated technique and results.
abstract: The purpose of this article is to reduce the incisional morbidity associated with standard radical retropubic prostatectomy using the minilaparotomy incision developed for pelvic lymph-node dissection, which was applied to radical retropubic prostatectomy. More than 522 patients underwent minilaparotomy radical retropubic prostatectomy from 1991 to 1997. Preoperative evaluation included history, physical examination, prostate-specific antigen (PSA), and Gleason's grade. Postoperative follow-up included serial PSA measurements and a determination of continence. The surgical technique is described in detail. Two hundred sixty-five patients responded to the mailed questionnaire out of a total 522 patients. Satisfactory continence, defined as 0 to 1 pad per day, was achieved in 85% of patients, and 83% of patients had a PSA < 0.2 at an average follow-up of 2.6 years. There was no operative mortality, and overall complication rate was similar to other surgeons. The typical patient was discharged home 3 days postoperatively. Minilaparotomy radical retropubic prostatectomy compares favorably with standard radical retropubic prostatectomy.
authors.affiliation: Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: P
authors.initials: P
authors.lastname: LaFontaine
authors.forename: D
authors.initials: D
authors.lastname: Chan
authors.forename: A W
authors.initials: AW
authors.lastname: Partin
authors.forename: R
authors.initials: R
authors.lastname: Gurganus
authors.forename: S C
authors.initials: SC
authors.lastname: Hortopan
authors.forename: F F
authors.initials: FF
authors.lastname: Marshall
mesh_terms: D006801:Humans; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000009:adverse effects / Q000379:methods*; D011184:Postoperative Period; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011471:Prostatic Neoplasms / Q000601:surgery*; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000517:prevention & control
chemical_list: D017430:Prostate-Specific Antigen